Histogen (HSTO) Stock Price, News & Analysis

Company Overview

Histogen, Inc. is a clinical‐stage biotechnology company headquartered in San Diego, California, that specializes in the development of regenerative medicine products for hair restoration and skin rejuvenation. The company’s proprietary technology harnesses the secreted growth factors, cytokines and extracellular matrix components produced by “embryonic‐like” human cells cultured under low‐oxygen conditions. By concentrating these biologically active molecules into a conditioned medium, Histogen aims to create off‐the‐shelf therapeutics that stimulate tissue repair and regeneration.

Histogen’s lead product candidates include HST‐001, a formulation under investigation for accelerating wound healing and improving skin quality, and HST‐002, a topical treatment designed to promote hair follicle health and counteract androgenetic alopecia. Both programs have advanced through initial clinical evaluations, demonstrating favorable safety profiles and signs of biological activity. The company holds a portfolio of patents protecting its cell‐culture processes and methods of use in dermatological and aesthetic indications.

Founded in 2007, Histogen operates research and GMP manufacturing facilities in the United States and collaborates with external laboratories and academic partners to expand its pipeline. Led by founder and Chief Executive Officer Christopher J. Bradley, the company continues to pursue late‐stage clinical development and strategic partnerships aimed at commercializing its regenerative therapeutics worldwide.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.05 to $0.55
• Volume: 153 shs
• Average Volume: 10,369 shs
• Market Capitalization: $854.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HSTO Stock Analysis - Frequently Asked Questions

How have HSTO shares performed this year?

Histogen's stock was trading at $0.0250 at the start of the year. Since then, HSTO shares have decreased by 99.2% and is now trading at $0.0002.

How were Histogen's earnings last quarter?

Histogen Inc. (NASDAQ:HSTO) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.20) by $0.40. The firm earned $0.59 million during the quarter.

When did Histogen's stock split?

Histogen's stock reverse split on Friday, June 3rd 2022.The 1-20 reverse split was announced on Friday, June 3rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Histogen?

Shares of HSTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Histogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Histogen investors own include Tesla (TSLA), Bionano Genomics (BNGO), Applied Genetic Technologies (AGTC), HubSpot (HUBS), Meta Platforms (META) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 10/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HSTO
• CIK: 1383701
• Web: www.histogen.com
• Phone: (858) 526-3100
• Fax: N/A
• Employees: 20
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $19 thousand
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.13 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 4,270,000
• Free Float: N/A
• Market Cap: $854.00
• Optionable: Not Optionable
• Beta: 1.19